<DOC>
	<DOCNO>NCT00002601</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug combine chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness high-dose combination chemotherapy peripheral stem cell transplantation treat patient advanced recurrent sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility sequential high-dose chemotherapy ifosfamide doxorubicin follow melphalan cisplatin , follow autologous peripheral blood stem cell support , patient high-risk advanced sarcoma . II . Determine toxic effect regimen patient . III . Determine response rate disease-free overall survival patient treat regimen . OUTLINE : Beginning least 4 week prior start chemotherapy , patient receive filgrastim ( G-CSF ) subcutaneously daily completion peripheral blood stem cell ( PBSC ) harvesting . Beginning 5 day start G-CSF , PBSCs collect several day . Patients mobilize sufficient cell undergo bone marrow harvest . Regimen A : Patients receive high-dose ifosfamide IV doxorubicin IV continuously 96 hour day -8 -4 . 12.5 % PBSCs bone marrow reinfused day -2 37.5 % reinfused day 0 . Patients receive G-CSF IV begin day 0 continue blood count recover . Regimen B : Beginning least 4 week day 1 Regimen A , patient receive high-dose melphalan IV follow immediately cisplatin IV day -11 -4 . Patients receive G-CSF IV day -10 -6 . 12.5 % PBSCs bone marrow reinfused day -3 remain 37.5 % reinfused day 0 . Patients receive G-CSF IV begin day 0 continue blood count recover . Patients follow monthly 1 year , every 3 month 1 year , need 3 year . PROJECTED ACCRUAL : A total 30 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm sarcoma follow category : Soft tissue sarcoma ( STS ) Highgrade STS extremities Primary extend fascia locally recurrent At least 10 cm great dimension multifocal surgical pathology Primary site control surgery and/or radiotherapy Highgrade truncal head neck sarcoma At least 10 cm great dimension size surgical option clear margin Primary site control surgery and/or radiotherapy Locally recurrent disease CR PR surgery , chemotherapy , radiotherapy Metastatic STS CR PR surgery , chemotherapy , radiotherapy Osteosarcoma ( OS ) Extremity OS neoadjuvant chemotherapy surgical resection provide : Less 50 % necrosis surgical specimen LDH alkaline phosphatase great 2 time normal presentation Axial OS CR PR chemotherapy and/or surgery Primary recurrent metastatic OS CR PR chemotherapy , surgery , and/or radiotherapy Ewing 's sarcoma primitive neuroectodermal tumor Primary site CR PR chemotherapy , radiotherapy , surgery Rib , pelvic , axial skeleton primary Bulky tumor ( least 10 cm great diameter ) Primary recurrent metastatic disease CR PR surgery , chemotherapy , radiotherapy Rhabdomyosarcoma Gross residual disease primary treatment surgery , chemotherapy , radiotherapy Primary group IV recurrent metastatic disease CR PR chemotherapy radiotherapy without surgery No brain metastasis No histologically confirm bone marrow metastasis Prior metastases allow clear bone marrow entry No contraindication collection mobilize stem cell , need , autologous bone marrow PATIENT CHARACTERISTICS : Age : 10 55 Performance status : Karnofsky 80100 % Hematopoietic : Absolute neutrophil count great 2,000/mm3 Platelet count great 150,000/mm3 Hemoglobin great 10 g/dL Hepatic : See Disease Characteristics Bilirubin le 1.5 mg/dL AST ALT less 3 time normal Hepatitis B surface antigen negative Negative hepatitis C antigen test require patient hepatitis C antibody Renal : Creatinine le 1.4 mg/dL Creatinine clearance great 75 mL/min Cardiovascular : LVEF least 55 % MUGA echocardiogram No history significant cardiac disease Pulmonary : FEV1 great 2 liter PaO2 great 70 mm Hg room air PaCO2 le 42 mm Hg room air DLCO great 60 % predict Other : No hearing loss great 40 decibel HIV negative No organic psychiatric CNS dysfunction would preclude study No medical psychosocial problem would place patient unacceptable risk No history malignancy except nonmelanoma skin cancer carcinoma situ cervix Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : More 2 week since treatment control primary recurrent tumor Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 2 prior chemotherapy regimen ( include adjuvant therapy ) Prior cumulative cisplatin dose le 400 mg/m2 Prior cumulative doxorubicin dose le 240 mg/m2 Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy 20 % bone marrowcontaining axial skeleton No prior radiotherapy leave chest wall Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>